Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H.

Clin Chem. 2019 Feb 8. pii: clinchem.2018.296814. doi: 10.1373/clinchem.2018.296814. [Epub ahead of print]

PMID:
30737205
2.

Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.

Fehm TN, Meier-Stiegen F, Driemel C, Jäger B, Reinhardt F, Naskou J, Franken A, Neubauer H, Neves RPL, van Dalum G, Ruckhäberle E, Niederacher D, Rox JM, Fischer JC, Stoecklein NH.

Cytometry A. 2018 Dec;93(12):1213-1219. doi: 10.1002/cyto.a.23669.

PMID:
30551262
3.

Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.

Huebner H, Fasching PA, Gumbrecht W, Jud S, Rauh C, Matzas M, Paulicka P, Friedrich K, Lux MP, Volz B, Gass P, Häberle L, Meier-Stiegen F, Hartkopf A, Neubauer H, Almstedt K, Beckmann MW, Fehm TN, Ruebner M.

BMC Cancer. 2018 Feb 20;18(1):204. doi: 10.1186/s12885-018-4115-1.

4.

Circulating tumor cells in breast cancer--current status and perspectives.

Banys-Paluchowski M, Krawczyk N, Meier-Stiegen F, Fehm T.

Crit Rev Oncol Hematol. 2016 Jan;97:22-9. doi: 10.1016/j.critrevonc.2015.10.010. Epub 2015 Oct 31. Review.

PMID:
26563820
5.

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.

Schramm A, Friedl TW, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni-Fabbroni M, Müller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Hartkopf A, Taran FA, Wallwiener D, Janni W, Fehm T.

Arch Gynecol Obstet. 2016 Feb;293(2):271-81. doi: 10.1007/s00404-015-3879-7. Epub 2015 Sep 9.

PMID:
26354331
6.

Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.

Banys-Paluchowski M, Schneck H, Blassl C, Schultz S, Meier-Stiegen F, Niederacher D, Krawczyk N, Ruckhaeberle E, Fehm T, Neubauer H.

Geburtshilfe Frauenheilkd. 2015 Mar;75(3):232-237.

7.

Molecular profiling of single circulating tumor cells with diagnostic intention.

Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B, Treitschke S, Schamberger T, Sergio M, Bregola G, Doffini A, Gianni S, Calanca A, Signorini G, Bolognesi C, Hartmann A, Fasching PA, Sandri MT, Rack B, Fehm T, Giorgini G, Manaresi N, Klein CA.

EMBO Mol Med. 2014 Nov;6(11):1371-86. doi: 10.15252/emmm.201404033.

8.

Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.

Neves RP, Raba K, Schmidt O, Honisch E, Meier-Stiegen F, Behrens B, Möhlendick B, Fehm T, Neubauer H, Klein CA, Polzer B, Sproll C, Fischer JC, Niederacher D, Stoecklein NH.

Clin Chem. 2014 Oct;60(10):1290-7. doi: 10.1373/clinchem.2014.222331.

9.

Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.

Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T.

Biomed Res Int. 2014;2014:415721. doi: 10.1155/2014/415721. Epub 2014 May 8. Review.

10.

Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients.

Krawczyk N, Hartkopf A, Banys M, Meier-Stiegen F, Staebler A, Wallwiener M, Röhm C, Hoffmann J, Hahn M, Fehm T.

BMC Cancer. 2014 Jun 3;14:394. doi: 10.1186/1471-2407-14-394.

11.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S.

Lancet Oncol. 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.

PMID:
24636208
12.

Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.

Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H.

Mol Oncol. 2013 Oct;7(5):976-86. doi: 10.1016/j.molonc.2013.07.007. Epub 2013 Jul 13.

13.

The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.

Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Röhm C, Hoffmann J, Helms G, Taran FA, Wallwiener M, Walter C, Neubauer H, Wallwiener D, Fehm T.

Breast Cancer Res Treat. 2013 Apr;138(2):509-17. doi: 10.1007/s10549-013-2470-9. Epub 2013 Mar 15.

PMID:
23494674
14.

Dormancy in breast cancer.

Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H.

Breast Cancer (Dove Med Press). 2012 Dec 5;4:183-91. doi: 10.2147/BCTT.S26431. Review.

15.

Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty--TEENDIAB: study design.

Ziegler AG, Meier-Stiegen F, Winkler C, Bonifacio E; TEENDIAB Study Group.

Pediatr Diabetes. 2012 Aug;13(5):419-24. doi: 10.1111/j.1399-5448.2011.00763.x. Epub 2011 Mar 29.

PMID:
21446926
16.

[Prospective observational studies of the development of type 1 diabetes during childhood and puberty].

Meier-Stiegen F, Ziegler AG.

Dtsch Med Wochenschr. 2011 Feb;136(6):271-5. doi: 10.1055/s-0031-1272523. Epub 2011 Feb 1. Review. German.

PMID:
21287431
17.

Activated Notch1 target genes during embryonic cell differentiation depend on the cellular context and include lineage determinants and inhibitors.

Meier-Stiegen F, Schwanbeck R, Bernoth K, Martini S, Hieronymus T, Ruau D, Zenke M, Just U.

PLoS One. 2010 Jul 8;5(7):e11481. doi: 10.1371/journal.pone.0011481.

18.

Cell-context specific target genes of Notch signaling: regulation by chromatin marks?

Schwanbeck R, Bernoth K, Martini S, Meier-Stiegen F, Hieronymus T, Ruau D, Zenke M, Just U.

J Stem Cells Regen Med. 2010 Oct 23;6(2):50. eCollection 2010. No abstract available.

PMID:
24693071
19.

Activated Notch1 alters differentiation of embryonic stem cells into mesodermal cell lineages at multiple stages of development.

Schroeder T, Meier-Stiegen F, Schwanbeck R, Eilken H, Nishikawa S, Häsler R, Schreiber S, Bornkamm GW, Nishikawa S, Just U.

Mech Dev. 2006 Jul;123(7):570-9. Epub 2006 May 25.

20.

Lipopolysaccharide-free heat shock protein 60 activates T cells.

Osterloh A, Meier-Stiegen F, Veit A, Fleischer B, von Bonin A, Breloer M.

J Biol Chem. 2004 Nov 12;279(46):47906-11. Epub 2004 Sep 14.

Supplemental Content

Loading ...
Support Center